FDA Issues Warning Letters on Marketing
and Sale of OTC CBD Products
By Seth Mailhot, Steve Levine, Emily Lyons, Leah Kaiser & Marshall Custer,
Husch Blackwell LLP
The FDA issued warning letters to two companies this month, alleging FD&C Act violations stemming from marketing new drugs without approval. Companies marketing CBD products should be careful not to market OTC drugs containing CBD.